Disease · MONDO_0044872
dysautonomia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. dysautonomia. Diseases, record MONDO_0044872. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0044872
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CETIRIZINE | CHEMBL1000 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FAMOTIDINE | CHEMBL902 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| DROXIDOPA | CHEMBL2103827 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ESMOLOL | CHEMBL768 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROPRANOLOL | CHEMBL27 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets11
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Adrenergic receptor | 3 | Adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 3 | Adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRA2A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/152 | Drugs and targets |
| ADRB3 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/155 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3269 | Drugs and targets |
1 to 10 of 11
See all 11 targetsTrials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05946551 | Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial | Phase 3 | 5 | 2025-07-17 | COVID-19 | CETIRIZINE, FAMOTIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT07398508 | NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease | Phase 1/2 | 6 | Menkes Disease | DROXIDOPA | Its record names the disease | ClinicalTrials.gov | |
| NCT04977388 | NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome | Phase 1/2 | 3 | Menkes Disease, Occipital Horn Syndrome | DROXIDOPA | Its record names the disease | ClinicalTrials.gov | |
| NCT01343329 | Controlling Hyperadrenergic Activity in Neurologic Injury | Phase 1/2 | 0 | Traumatic Brain Injury, Dysautonomia | ESMOLOL, PROPRANOLOL | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| HRA Treatment Arm vs Placebo Arm: Proportion of Survey Completion | 3 of 3 | 2 of 2 | 5 | NCT05946551 | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Prefer Participating in This Virtual Study | 3 of 3 | 2 of 2 | 5 | NCT05946551 | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Felt That the Frequency in Which the Information Was Collected Was Acceptable | 3 of 3 | 2 of 2 | 5 | NCT05946551 | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Proportion of Voluntary Termination | 0 of 3 | 0 of 2 | 5 | NCT05946551 | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants Satisfied With Their Opportunities to Interact With Study Staff | 3 of 3 | 2 of 2 | 5 | NCT05946551 | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Felt That Study Staff Was Available and Easy to Contact to Report Any Adverse Effects | 3 of 3 | 2 of 2 | 5 | NCT05946551 | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Proportion of Lost to Follow Up (LFUP) | 0 of 3 | 0 of 2 | 5 | NCT05946551 | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Proportion of Study Drug Adherence | 3 of 3 | 2 of 2 | 5 | NCT05946551 | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Felt That the Amount of Information Collected in Each Series of Surveys Was Acceptable | 3 of 3 | 2 of 2 | 5 | NCT05946551 | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Had Any Confusion Over How to Take the Study Drug, Including Which Pill to Take, When to Take it, or How Many to Take | 0 of 3 | 0 of 2 | 5 | NCT05946551 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 42016919 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044872
GET https://conductscience.org/api/diseases/v1/MONDO_0044872/drugs